RSUME与垂体腺瘤侵袭性的分子机制研究进展

何伟; 王大鹏; 沈晓黎

doi:10.3969/j.issn.1000-8179.20131652

RSUME与垂体腺瘤侵袭性的分子机制研究进展

doi: 10.3969/j.issn.1000-8179.20131652

南昌大学第二附属医院神经外科（南昌市 330006）

详细信息

作者简介:
何伟在读硕士研究生。研究方向为侵袭性垂体腺瘤的基础及临床研究。E-mail：hewei1456@sina.com

通讯作者:
沈晓黎 E-mail:shenxldoc@126.com

计量
- 文章访问数: 7
- HTML全文浏览量: 14
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2013-10-07
- 修回日期: 2013-12-02
- 网络出版日期: 2013-12-11
- 刊出日期: 2020-12-31

Research Progress in molecular mechanisms between RSUME and invasive pituitary adenoma

Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

More Information

Corresponding author: Xiaoli SHEN; E-mail:shenxldoc@126.com

摘要

摘要: 垂体腺瘤为颅内良性肿瘤，但却是成年人脑肿瘤的第三大常见肿瘤，仅次于神经胶质瘤和脑膜瘤。垂体腺瘤定义为良性肿瘤，但部分垂体腺瘤可对周围组织有侵袭性，手术难以切除，术后易复发。RWD结构修饰增强子（RWD containing sumoylation enhancer，RSUME），可在垂体腺瘤中通过小泛素化（small ubiquitin related modifiers，SUMO）稳定缺氧诱导因子-1α（hypoxia inducible factor-1α，HIF-1α）以及抑制分子kappaB（inhibitor kappaB，IκB）的活性，促进垂体腺瘤的侵袭作用。RSUME对体腺瘤的侵袭性起着重要的作用，但RSUME的作用与垂体腺瘤侵袭的相关性尚未明确。本文就RSUME对垂体腺瘤侵袭作用中HIF-1α/VEGF信号通路以及IκB/NF-κB复合体的作用进行综述。
- RSUME /
- 垂体腺瘤 /
- 侵袭性分子机制
Abstract: Pituitary adenoma, a benign intracranial tumor, is the third most common brain tumor, second only to glioma and meningioma. Pituitary adenoma has been defined as a benign tumor, but some pituitary adenomas can invade the surrounding tissue. Thism tumor is difficult to resect and can easily recur after surgery. RWD-containing sumoylation enhancer (RSUME) can stabilize the activity of hypoxia-inducible factor-1α and inhibitor kappaB by the small ubiquitin-related modifiers. This phenomenon indicates the importance of RSUME in pituitary adenoma because it promotes the invasiveness of the tumor. However, the correlation between RSUME and the invasion of pituitary adenoma remains unclear. In this study, the roles of RSUME on HIF-1α/VEGF signaling pathway and IκB/NF-κB compomers in the invasiveness of pituitary adenoma were reviewed.
- RSUME /
- pituitary adenoma /
- invasive molecular mechanisms

HTML全文

参考文献(21)

[1]	Carbia-Nagashima A, Gerez J, Perez-Castro C, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia[J]. Cell, 2007, 131(2):309-323. doi: 10.1016/j.cell.2007.07.044
[2]	Li R, Wei J, Jiang C, et al. Akt SUMOylation regulates cell proliferation and tumorigenesis[J]. Cancer Res, 2013, 73(18):5742-5753. doi: 10.1158/0008-5472.CAN-13-0538
[3]	Srikumar T, Lewicki MC, Raught B. A global S. cerevisiae small ubiquitin-related modifier(SUMO) system interactome[J]. Mol Syst Biol, 2013, 9:668. doi: 10.1038/msb.2013.23
[4]	Hsieh YL, Kuo HY, Chang CC, et al. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response[J]. EMBO J, 2013, 32(6):791-804. http://cn.bing.com/academic/profile?id=315eb29e1048d8ea5fdb30e5f4bca28d&encoded=0&v=paper_preview&mkt=zh-cn
[5]	Cubeñas-Potts C, Matunis MJ. SUMO: a multifaceted modifier of chromatin structure and function[J]. Dev Cell, 2013, 24(1):1-12. doi: 10.1016/j.devcel.2012.11.020
[6]	Cimarosti H, Ashikaga E, Jaafari N, et al. Enhanced SUMOylation and SENP-1 protein levels following oxygen and glucose deprivation in neurones[J]. J Cereb Blood Flow Metab, 2012, 32(1):17-22. doi: 10.1038/jcbfm.2011.146
[7]	Núñez-O'Mara A, Berra E. Deciphering the emerging role of SUMO conjugation in the hypoxia-signaling cascade[J]. Biol Chem, 2013, 394(4):459-469. doi: 10.1515/hsz-2012-0319
[8]	Berta MA, Mazure N, Hattab M, et al. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity[J]. Biochem Biophys Res Commun, 2007, 360(3):646-652.
[9]	Chan JY, Tsai CY, Wu CH, et al. Sumoylation of hypoxia-inducible factor-1α ameliorates failure of brain stem cardiovascular regulation in experimental brain death[J]. PLoS One, 2011, 6(3):e17375. doi: 10.1371/journal.pone.0017375
[10]	Shan B, Gerez J, Haedo M, et al. RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells[J]. Endocr Relat Cancer, 2012, 19(1):13-27. http://cn.bing.com/academic/profile?id=6960d5ceb844a76c1acbc9752788d522&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Gray RT, O'Donnell ME, Maxwell P, et al. Long-term follow-up of immunocytochemical analysis of vascular endothelial growth factor (VEGF), and its two receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR), in oesophagogastric cancer[J]. Int J Biol Markers, 2013, 28(1):63-70. doi: 10.5301/JBM.2012.10433
[12]	沈晓黎, 邓志锋, 祝新根, 等. VEGF及其受体表达与垂体腺瘤血管生成和侵袭性的关系[J].中国微侵袭神经外科杂志, 2011, 16(3):132-135.] Shen XL, Deng ZF. Zhu XG, et al. Correlation between the expres sion of vascular endothelial growth factor/KDR and angiogenesis and invasion in human pituitary adenomas[J]. Chin J Minim Invasive Neurosurg, 2011, 16(3):132-135.
[13]	Hu X, Xing L, Wei X, et al. Nonangiogenic function of VEGF and enhanced radiosensitivity of HeLa cells by inhibition of VEGF expression[J]. Oncol Res, 2012, 20(2-3):93-101. doi: 10.3892/etm.2018.5964
[14]	Benderro GF, Sun X, Kuang Y, et al. Decreased VEGF expression and microvascular density, but increased HIF-1 and 2α accumulation and EPO expression in chronic moderate hyperoxia in the mouse brain[J]. Brain Res, 2012, 1471:46-55. doi: 10.1016/j.brainres.2012.06.055
[15]	Kim K, Yoshida D, Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas[J]. Endocr Pathol, 2005, 16(2):115-121. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868239/
[16]	Fuertes M, Gerez J, Haedo M, et al. Cytokines and genes in pituitary tumorigenesis: RSUME role in cell biology[J]. Front Horm Res, 2010, 38:1-6. doi: 10.1159/000318488
[17]	Fowkes RC, Vlotides G. Hypoxia-induced VEGF production 'RSUMEs' in pituitary adenomas[J]. Endocr Relat Cancer, 2012, 19(1): C1-5. http://cn.bing.com/academic/profile?id=62085f15fc4e2d434eec2afc98af6522&encoded=0&v=paper_preview&mkt=zh-cn
[18]	Xia Z, Liu W, Li S, et al. Expression of matrix metalloproteinase-9, type Ⅳ collagen and vascular endothelial growth factor in adamantinous craniopharyngioma[J]. Neurochem Res, 2011, 36(12):2346-2351. doi: 10.1007/s11064-011-0560-9
[19]	Lens Z, Dewitte F, Van Lint C, et al. Purification of SUMO-1 modified IκBα and complex formation with NF-κB[J]. Protein Expr Purif, 2011, 80(2):211-216. doi: 10.1016/j.pep.2011.06.009
[20]	Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker[J]. Nat Immunol, 2011, 12(8):715-723. doi: 10.1038/ni.2060
[21]	Zhao J, Rao DS, Boldin MP. NF-κ B dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies[J]. Proc Natl Acad Sci U S A, 2011, 108(22):9184-9189. doi: 10.1073/pnas.1105398108